Immune-related adverse events - Globe Thesis

Keyword [Immune-related adverse events] Result: 21 - 38 \| Page: 2 of 2
21.	The Exploration Of Personalized Therapeutic Strategy And Promising Biomarkers For Patients With Triple-negative Breast Cancer
22.	Dicer Enhances The Anti-Tumor Effect Of Lenvatinib Through Interleukin-8 In Hepatocellular Carcinoma And The Relationship Between Interleukin-8 And Immune Related Adverse Events
23.	Study On The Protective Effect And Mechanism Of Vitamin D₃ Combined With Lactobacillus Rhamnosus On Colitis Associated With Tumor Immunotherap
24.	The Safety Of Immune Checkpoint Inhibitors Monotherapy Or Combined Therapy Of Non-small Cell Lung Cancer:A Systematic Review And Network Meta-analysis
25.	Real World Study Of Immune Related Adverse Events Caused By PD-1 Inhibitors And Efficacy Correlation
26.	The Role Of Inflammatory Markers In Predicting The Efficacy And Safety Of Anti-PD-1 Therapy In Advanced Non-small Cell Lung Cancer
27.	A Comparative Study Of Immune Checkpoint Inhibitor-associated Thyroiditis And Hashimoto Thyroiditis
28.	Predict Valve Of Peripheral Blood Immune Cells Level In Immune-related Adverse Events
29.	Application Of Peripheral Blood Markers To Predict Immune-Related Toxicity And Prognosis In Patients With Advanced Non-Small Cell Lung Cancer
30.	Construction Of A Symptom Self-Report Scale For Cancer Immunotherapy Patients
31.	Study On Early Risk Factors Of Clinical Features For IrAEs In Primary Hepatocellular Carcinoma Treated With PD-1 Antibody Combined With TKI And The Relationship Between IrAEs And Outcomes
32.	Efficacy And Safety Of Durvalumab + Chemotherapy Vs. Atezolizumab + Chemotherapy In The Treatment Of Small-cell Lung Cancer
33.	A Study On The Application Of Nanomedicines Based On Removing Physical Barriers To Enhance Immunotherapy In HCC
34.	Clinical Feature,prognostic Impact And Risk Factor Of Checkpoint Inhibitor Related Pneumonitis In Patients With Non-Small Cell Lung Cancer
35.	Treatment Response And Safety Of Immunotherapy For Advanced Non-small Cell Lung Cancer With Comorbid Chronic Obstructive Pulmonary Disease
36.	Study Of IrAEs Caused By Camrelizumab For Malignant Tumors And Related Factors
37.	The Value Of LIPI,ALI And IrAe In Evaluating The Efficacy And Prognosis Of Immunotherapy In Patients With Lung Adenocarcinoma In Stage Ⅳ
38.	Study On The Correlation Between Traditional Chinese Medicine(TCM)constitution,syndrome Type And Immune-Related Adverse Events(irAEs)in Advanced Non-small Cell Lung Cancer(NSCLC)
<<First <Prev Next> Last>> Jump to